08:53 AM EST - Oncolytics Biotech Inc : Today announces phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma. The data are featured in an abstract accepted for a poster presentation at the upcoming American Association for Cancer Research Annual Meeting, which is taking place both virtually and in-person April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The abstract is also posted on the AACR meeting website. Oncolytics Biotech Inc
shares T.ONC are trading up $0.05 at $2.02.
